01Approach to the Critical Patient/attcp44

Immediate resuscitation priorities

›Anaphylaxis recognition and treatment

›Urticaria, angioedema, bronchospasm, hypotension after known or suspected cyst rupture

›Epinephrine IM 0.3–0.5 mg (1:1000) immediately

›Repeat at 5–15 minutes if inadequate response

›IV access with two large-bore cannulas

›Crystalloid bolus 1–2 L IV for hypotension

›Diphenhydramine 50 mg IV and ranitidine 50 mg IV adjuncts

›Supine positioning with legs elevated unless respiratory distress

›Airway compromise may require sitting position

›Monitor for biphasic reaction up to 72 hours

›Hemodynamic stabilization targets

›MAP >= 65 mmHg

›Norepinephrine 0.1–0.3 mcg/kg/min if fluid-refractory hypotension

›Vasopressin 0.03–0.04 units/min adjunct

›SpO2 >= 94%

›High-flow oxygen 10–15 L/min via non-rebreather mask

›Early intubation if airway compromise from angioedema

›Continuous cardiac monitoring for dysrhythmia

›Kounis syndrome (coronary vasospasm from anaphylaxis) rare but life-threatening

Surgical emergency actions

›Immediate surgical consultation

›Intraperitoneal rupture is operative emergency

›Peritonitis with free fluid on POCUS triggers immediate OR

›Damage control surgery principles if unstable

›Biliary tree rupture indication for urgent ERCP or surgery

›Obstructive jaundice with cholangitis requires urgent biliary decompression

›Pulmonary cyst rupture with respiratory failure

02History/hx66

Presenting symptoms

›Core symptom complex

›Acute severe abdominal pain

›Most common presenting complaint

›Sudden onset, may radiate to right shoulder if diaphragm irritated

›Anaphylaxis symptoms

›Urticaria and pruritus

›Angioedema of lips, tongue, pharynx

›Dyspnea and wheezing

›Syncope or near-syncope

›Nausea and vomiting

›Peritoneal irritation

›Vagal response to pain

›Rupture type-specific symptoms

›Intraperitoneal rupture

›Acute abdomen with diffuse peritonitis

›Sudden urticaria accompanying abdominal pain is pathognomonic

›Biliary rupture

›Jaundice, dark urine, pale stools

›Fever and rigors if secondary cholangitis (Charcot's triad)

›Pulmonary cyst rupture

›Sudden-onset chest pain and dyspnea

›Vomica: expectoration of salty fluid with grape-skin membranes

›Hemoptysis if vascular involvement

Epidemiological history

›Geographic and travel exposure

›Residence in or travel to endemic regions

›South America, Eastern Europe, Russia, Middle East

03Physical Exam/exam58

Vitals and hemodynamic assessment

›Stability snapshot

›Blood pressure

›Hypotension (SBP < 90 mmHg) in up to 75% of intraperitoneal rupture cases

›Anaphylactic shock pattern: distributive, warm peripheries initially

›Heart rate

›Tachycardia universal in hemodynamically significant rupture

›Bradycardia may indicate vasovagal response or Kounis syndrome

›Respiratory rate

›Tachypnea from bronchospasm, pain, or pleural involvement

›Temperature

›Fever suggests secondary infection of ruptured cyst or cholangitis

›SpO2

›Desaturation with pulmonary cyst rupture or severe bronchospasm

Skin and allergic manifestations

›Cutaneous allergic signs

›Urticaria

›Generalized hives from systemic antigen release

›Pathognomonic when accompanying acute abdominal pain

›Angioedema

›Periorbital, labial, and laryngeal involvement

›Stridor indicates impending airway compromise

›Flushing and erythema

›Mast cell degranulation from antigenic cyst fluid

›Pallor and diaphoresis

›Hemodynamic compromise marker

Abdominal examination

›Peritoneal signs

04Differential Diagnosis/ddx51

Life-threatening diagnoses

›Anaphylaxis from other causes

›Drug-induced anaphylaxis

›Medication exposure within minutes to 1 hour

›ICD-10 T78.2 anaphylactic shock

›Food-induced anaphylaxis

›Peanut, shellfish, tree nut exposure

›No abdominal mass on imaging

›Insect sting anaphylaxis

›Hymenoptera exposure history

›Acute abdomen from other cause

›Perforated peptic ulcer

›ICD-10 K27.1

›Free air under diaphragm on upright CXR

›No cystic lesion on imaging

›Acute appendicitis with perforation

›ICD-10 K35.2

›RLQ pain migration pattern

›Ruptured ectopic pregnancy

›Positive beta-hCG in women of reproductive age

›No cystic hepatic lesion

›Septic shock

›Pyogenic hepatic abscess

›ICD-10 K75.0

›Fever, leukocytosis, no anaphylaxis

›Ascending cholangitis

›ICD-10 K83.0

›Charcot's triad without cyst imaging finding

05Laboratory Tests/lt58

Allergy and anaphylaxis markers

›Serum tryptase

›Elevated within 1–3 hours of mast cell degranulation

›Supports anaphylaxis diagnosis

›Peak at 1 hour, returns to baseline by 6 hours

›Collect during acute episode if possible

›Repeat at 24 hours as baseline comparator

›Complete blood count

›Eosinophilia

›Peripheral eosinophilia associated with cyst leakage and allergic response

›May be absent in 25–40% of cases

›Leukocytosis

›Secondary infection of ruptured cyst or cholangitis

›Anemia

›Hemorrhagic rupture with hemoperitoneum

Hepatobiliary and metabolic labs

›Comprehensive metabolic panel

›Bilirubin elevated in biliary rupture

›Conjugated hyperbilirubinemia with biliary obstruction

›Alkaline phosphatase and GGT

›Elevated with biliary communication or cholangitis

›Transaminases

›Mild to moderate elevation with hepatic parenchymal involvement

›Creatinine and electrolytes

›Baseline for IV contrast and albendazole dosing

›Hyponatremia if massive peritoneal fluid accumulation

›Coagulation studies

›PT/INR and aPTT

06Diagnostic Tests/dt74

Scoring Systems

›WHO-IWGE cyst classification (CE1–CE5)

›CE1: Active phase, unilocular anechoic cyst with double-line sign

›Highly viable cysts with intact germinal layer

›PAIR is an option for uncomplicated CE1

›CE2: Active phase, multivesicular cyst with daughter cysts (honeycomb)

›High viability and high risk of rupture

›CE3a: Transitional phase, cyst with detached endocyst membrane (water-lily sign)

›CE3a indicates early rupture or degeneration

›CE3b contains daughter cysts; higher relapse rate

›CE4: Inactive phase, heterogeneous matrix without daughter cysts

›Low or absent viability

›CE5: Inactive phase, calcified cyst wall

›Usually requires no treatment unless symptomatic

›Classification guides treatment modality selection

›Active stages (CE1, CE2, CE3) favor surgical or PAIR intervention

›Inactive stages (CE4, CE5) may be monitored

MRI

›MRI abdomen indications

›Superior biliary communication assessment

›Cystobiliary fistula detection: sensitivity superior to CT

›Critical pre-operative information for surgical planning

›Cyst characterization when CT equivocal

›Intermediate T1 signal with proteinaceous debris

›T2 hypointense rim (pericyst) is characteristic

›Detached germinal membrane on T2-weighted imaging

›Water-lily appearance confirming rupture

›MRCP for biliary tree evaluation

›Non-invasive alternative to ERCP in stable patients

›Delineates biliary anatomy before surgical intervention

›MRI limitations

›Unstable patients: contraindicated due to monitoring constraints

›Availability and time constraints in emergency setting

›Motion artifact from pain and respiratory rate

CT

›CT abdomen and pelvis with IV contrast

›Primary indication in rupture

›Confirms extent of rupture and free fluid

›Identifies daughter cysts in peritoneal cavity

›Cyst wall discontinuity is hallmark of rupture

›Peritoneal seeding assessment

›Secondary hydatidosis: multiple peritoneal implants

›Distribution and volume of implants guide surgical extent

›Calcification pattern

›Calcified cyst wall may indicate prior or ongoing CE5 stage

›Peripheral eggshell calcification

›CT chest indications

›Pulmonary involvement workup

›Cyst morphology: air-fluid level within cyst (water-lily sign)

›Pneumothorax, hydropneumothorax, or pleural effusion

›Diaphragmatic involvement assessment

›Transdiaphragmatic rupture between hepatic and pulmonary cavities

›CT-guided interventions

›Not indicated for ruptured cysts (spillage risk)

›Role limited to pre-operative planning and drainage of secondary collections

Ultrasound

›Abdominal ultrasound (first-line imaging for hepatic CE)

›Reference standard for hepatic cyst staging

›WHO-IWGE classification applied by ultrasound morphology

›Sensitivity approaches 90–95% for hepatic cysts

›Rupture findings on ultrasound

›Discontinuous cyst wall

›Floating collapsed membranes (water-lily sign)

›Free intraperitoneal fluid with echogenic particles

›Daughter cysts outside the parent cyst

›Limitations

›Operator-dependent

›Gas-containing bowel may obscure cyst margins

›POCUS in emergency setting

›Free fluid detection (FAST protocol)

›Morison's pouch, splenorenal recess, pelvis

›Quantify hemoperitoneum or cyst fluid spillage

›Biliary assessment

›Common bile duct dilation indicating obstruction

›Intrahepatic biliary dilation pattern

›Cardiac POCUS

›LV function in distributive shock

›Pericardial effusion if cardiac hydatid cyst present (rare, approx 1% of cases)

07Disposition/dispo33

Admission and surgical criteria

›All ruptured hydatid cysts require hospital admission

›No safe outpatient management of confirmed or suspected rupture

›Risk of anaphylaxis relapse (biphasic reaction) up to 72 hours

›Risk of peritonitis progression

›Surgical consultation mandatory for all intraperitoneal ruptures

›Operative intervention typically within hours of diagnosis

›Biliary rupture

›GI or hepatobiliary surgical consultation

›ERCP team notification for sphincterotomy and stenting

Level of care determination

›ICU criteria

›Refractory anaphylaxis or anaphylactic shock

›Vasopressor requirement

›Ongoing bronchospasm requiring continuous nebulizers

›Septic shock from secondary infection

›Lactate >= 2 mmol/l with organ dysfunction

›Norepinephrine infusion requirement

›Post-operative monitoring after emergency laparotomy

›Hemorrhagic or septic complications

›Respiratory failure requiring mechanical ventilation

›Step-down or general surgical ward

›Hemodynamically stable after resuscitation

›No vasopressor requirement

›Tolerating oral medications

›Albendazole initiation and monitoring required

›Infectious disease or tropical medicine consultation recommended

08Treatment/t83

Anaphylaxis management

›First-line treatment

›Epinephrine IM 0.3–0.5 mg (1:1000 solution)

›Anterolateral mid-thigh injection preferred

›Repeat every 5–15 minutes if inadequate response

›Maximum 3 doses IM before IV route consideration

›IV epinephrine infusion for refractory anaphylaxis

›0.1–1 mcg/kg/min titrated to hemodynamic response

›ICU monitoring mandatory

›Adjunctive therapies

›Diphenhydramine 25–50 mg IV or IM

›H1 blocker reduces urticaria and angioedema

›Not first-line, never replaces epinephrine

›Ranitidine 50 mg IV or famotidine 20 mg IV

›H2 blocker adjunct

›Methylprednisolone 125 mg IV or hydrocortisone 200 mg IV

›Reduces biphasic reaction risk

›Onset delayed 4–6 hours

›Salbutamol 2.5–5 mg nebulized for bronchospasm

›Adjunct to epinephrine for lower airway obstruction

Antihelminthic therapy

›Albendazole (first-line)

›Adults >= 60 kg: 400 mg PO BID with fatty meal

›28-day cycles with 14-day drug-free intervals (FDA label)

›Current expert consensus supports continuous dosing in peri-rupture period

›Duration: 1–6 months post-surgery depending on response

›Adults < 60 kg: 15 mg/kg/day PO divided BID

›Maximum daily dose 800 mg

›Initiate immediately in ED to prevent secondary peritoneal seeding

›Cyst fluid seeding of peritoneum creates secondary hydatidosis

›Most critical window is peri-operative period

›Absorption enhanced by fatty meals

›Avoid fasting administration

›Alternative antihelminthic

›Mebendazole 40–50 mg/kg/day PO divided TID

›Second-line when albendazole not available

›Inferior oral bioavailability compared to albendazole

›Also enhanced by fatty meal co-administration

›Contraindications and precautions

›Albendazole contraindicated in first trimester of pregnancy

›Monitoring CBC and LFTs every 2 weeks throughout treatment

›Hepatotoxicity requires dose interruption or cessation

Surgical management

›Intraperitoneal rupture

›Emergency laparotomy

›Aspiration of cyst contents with large-bore sucker

›Intraoperative scolicidal agent instillation: hypertonic saline 20%

›Leave for minimum 10 minutes before aspiration

›Pericystectomy (total or partial) or hepatic resection

›Extent depends on cyst location and hepatic reserve

›Peritoneal lavage with hypertonic saline

›Eliminate daughter cysts from peritoneal cavity

›Drain placement for peritoneal contamination

›Biliary rupture

›ERCP with sphincterotomy and stenting

›Decompress biliary tree before or instead of surgery in stable patients

›Remove daughter cysts from common bile duct

›Surgical common bile duct exploration if ERCP fails

›T-tube drainage

›Pulmonary cyst rupture

›Thoracoscopic or open cystectomy

›Capitonnage (closure of remaining cavity) preferred

›Bronchopleural fistula management

›May require lobectomy in complex cases

›Post-operative albendazole continuation

›PAIR procedure (not for ruptured cysts)

›Puncture-Aspiration-Injection-Re-aspiration

›Contraindicated in ruptured cysts

›Contraindicated when biliary communication present

›Used for intact uncomplicated CE1 or CE3a cysts

Infection control and antibiotics

›Antibiotics for secondary infection

›Piperacillin-tazobactam 4.5 g IV every 6 hours

›First-line for biliary or peritoneal contamination

›Gram-negative and anaerobic coverage

›Alternative: ceftriaxone 2 g IV daily plus metronidazole 500 mg IV every 8 hours

›Biliary penetration for cholangitis management

›If septic shock: broaden to carbapenem (meropenem 1 g IV every 8 hours)

›Duration: 5–14 days depending on source control adequacy

›Prophylactic antibiotics

›Cefazolin 1–2 g IV single dose pre-operative

›No evidence for routine prophylactic antibiotics absent secondary infection

Corticosteroid and prolonged allergy management

›Prolonged corticosteroid course for eosinophilic or systemic allergic response

›Prednisone 40–60 mg PO daily tapered over 2–4 weeks

›When ongoing eosinophilia-related organ dysfunction

›Consult infectious disease or allergy/immunology

›Not routine for all rupture cases

09Special Populations/sp68

Pregnancy

›Physiologic considerations

›Increased intraabdominal pressure and cyst compression risk

›Third trimester highest mechanical rupture risk

›Immunologic tolerance of pregnancy may alter serologic response

›Serology less reliable in pregnancy

›Antihelminthic safety

›Albendazole contraindicated in first trimester

›Teratogenic in animal models; insufficient human safety data

›FDA Pregnancy Category C (old classification)

›Second and third trimester: weigh benefit-risk carefully

›Defer elective albendazole therapy to post-partum if cyst stable

›Emergency rupture may justify use after first trimester with specialist guidance

›Mebendazole similarly teratogenic risk profile

›Surgical considerations

›Surgery in pregnancy for ruptured cyst is generally required regardless of trimester

›Maternal life takes priority

›Obstetric and maternal-fetal medicine consultation

›Fetal heart rate monitoring peri-operatively when viable

›Regional anesthesia preferred when feasible

›Imaging

›Ultrasound is imaging modality of choice in pregnancy

›No ionizing radiation risk to fetus

›MRI without gadolinium acceptable when ultrasound insufficient

›Avoid gadolinium contrast in pregnancy unless mandatory

›CT only when life-threatening emergency mandates it

›Fetal radiation dose counseling required

Geriatric

›Atypical presentation

›Blunted anaphylaxis response in older adults

›Beta-blocker use may attenuate tachycardia and mask severity

›Epinephrine still first-line; glucagon 1–2 mg IV if beta-blocked

›Higher baseline comorbidity affecting surgical risk

›Cardiac and pulmonary reserve assessment critical

›Drug considerations

›Albendazole hepatotoxicity risk higher with pre-existing liver disease

›Careful baseline LFT assessment and more frequent monitoring

›Renal adjustment for antibiotics

›Piperacillin-tazobactam: GFR-based dose adjustment

›Polypharmacy interaction review

›Albendazole is CYP3A4 inducer; interaction with anticoagulants

›Surgical risk modification

›High-risk patients may be candidates for non-operative management

›Interventional radiology drainage of contained rupture

›Multidisciplinary team decision

›Frailty assessment influences disposition and post-operative care needs

›Admission to geriatric surgery or high dependency unit preferred

Pediatrics

›Epidemiology in children

›Children represent up to 40% of cases in highly endemic regions

›Most symptomatic cases present in ages 5–15 years

›Rupture less common in children due to smaller cyst size at presentation

›Antihelminthic dosing

›Albendazole 15 mg/kg/day PO divided BID

›Maximum 800 mg/day

›Administer with fatty meal for absorption

›Same monitoring intervals: CBC and LFTs every 2 weeks

›Surgical approach

›Children generally tolerate surgery well

›Cyst-preserving conservative surgery preferred to avoid hepatic resection

›Pediatric surgery consultation essential

›Spill precautions same as adults

›Hypertonic saline scolex ablation intraoperatively

›Anaphylaxis dosing

›Epinephrine IM 0.01 mg/kg (1:1000) up to 0.5 mg maximum per dose

›Weight-based dosing mandatory

›Anterolateral mid-thigh injection

›Diphenhydramine 1 mg/kg IV up to 50 mg maximum

›Imaging preference

›Ultrasound first-line to avoid radiation

›CT only when ultrasound insufficient and emergency planning required

10Background/b76

Epidemiology

›Global burden

›Cystic echinococcosis (CE) endemic in 100+ countries

›Estimated 1–3 million cases worldwide at any time

›Global burden estimated at 1–3 million DALYs annually

›Highest incidence in sheep-raising and cattle-farming regions

›South America (Argentina, Uruguay, Peru), Mediterranean basin

›Central Asia, China, Eastern Europe, East Africa

›Annual incidence 1–200 per 100,000 population in endemic zones

›Demographics

›Most symptomatic cases in adults aged 21–40 years in endemic areas

›Long latency from infection (egg ingestion) to clinical presentation

›Children up to 40% of cases in highly endemic regions

›Equal sex distribution overall; occupational exposure creates male predominance in some cohorts

›Rupture incidence

›Spontaneous or trauma-induced rupture occurs in 5–25% of CE cases

›Intraperitoneal rupture is the most common and most dangerous

›Biliary rupture is most common form of complication overall

›Mortality from ruptured hydatid cyst: 1–10% with treatment; higher without

›Secondary hydatidosis (peritoneal seeding) occurs in 10–30% of intraperitoneal ruptures not treated with anti-scolicidal agents

Pathophysiology

›Parasite lifecycle

›Definitive host: Canis lupus familiaris (dog) and other canids

›Adult Echinococcus granulosus tapeworm lives in small intestine

›Eggs shed in feces contaminate water, soil, vegetation

›Intermediate host: sheep, cattle, humans (dead-end host)

›Humans ingest eggs via contaminated food, water, or fomites

›Oncosphere (hexacanth embryo) penetrates intestinal wall

›Hepatic and pulmonary tropism

›Liver: first-pass organ, 70–80% of human CE

›Lungs: second filter, 15–20% of human CE

›Other sites (brain, bone, kidney, spleen): < 5%

›Cyst development

›Three-layer cyst structure

›Pericyst: host-derived outer fibrotic layer

›Ectocyst (laminated membrane): parasite-derived, outer

›Germinal layer (endocyst): inner living parasite epithelium producing daughter cysts and protoscoleces

›Protoscoleces: juvenile tapeworm heads, highly antigenic

›Release into host cavity triggers massive IgE-mediated response

›Hydatid sand: mixture of protoscoleces, free hooklets, and brood capsules

›Rupture consequences

›Anaphylaxis: sudden release of highly antigenic cyst fluid

›IgE-mediated mast cell degranulation systemically

›Secondary hydatidosis: peritoneal or pleural seeding with viable protoscoleces

›Each protoscolex can develop into a new cyst

›Seeding causes disseminated disease if not treated

›Chemical peritonitis from irritant cyst fluid

›Biliary obstruction and cholangitis from daughter cysts in biliary tree

Therapeutic Considerations

›Antihelminthic therapy rationale

›Albendazole penetrates cyst wall via hydrophilic diffusion

›Active metabolite albendazole sulfoxide is scolicidal

›Reaches 10–20% of plasma concentration within cyst fluid

›Pre-operative albendazole reduces cyst viability

›Minimum 4 days recommended before elective surgery

›May not be achievable in emergency rupture setting

›Post-operative continuation mandatory to prevent recurrence

›Duration 1–6 months per WHO recommendation

›Longer duration for secondary hydatidosis

›Surgical principles

›Radical surgery (total pericystectomy or hepatic resection) reduces recurrence

›Recurrence rate after conservative surgery: 10–30%

›Recurrence after radical surgery: < 5%

›Anti-scolicidal agent contact time critical

›Hypertonic saline 20% minimum 10 minutes contact

›Alternative: cetrimide 0.5% or 70% ethanol

›Risk of sclerosing cholangitis if biliary communication present: avoid hyperosmolar solutions

›Laparoscopic approach for selected uncomplicated cases

›Not recommended in rupture scenario due to spillage risk

›PAIR rationale and limitations

›Percutaneous aspiration with scolicidal agent injection for uncomplicated cysts

›Effective for CE1 and CE3a stages

›Contraindicated in rupture: risk of anaphylaxis and peritoneal seeding

›WHO/IWGE guidelines support PAIR as alternative to surgery for uncomplicated CE

›Monitoring post-treatment

›Ultrasound follow-up every 3–6 months for 2 years post-treatment

›Cyst regression stages E toward CE4/CE5 indicate therapeutic success

›Serology may remain positive for years after successful treatment

›Not reliable marker of cure; imaging-based follow-up preferred

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Echinococcosis (hydatid cyst) — home care after treatment

›Take all antiparasitic medication (albendazole) exactly as prescribed

›Always take with a fatty meal (eggs, milk, peanut butter) to improve absorption

›Do not stop taking without medical advice even if feeling better

›Return for blood test monitoring every 2 weeks while on medication

›Medication can affect your liver and blood counts

›Avoid heavy lifting or strenuous activity until cleared by surgeon

›Keep all surgical follow-up appointments

›Allergy warning after rupture

›You had a severe allergic reaction (anaphylaxis) during your illness

›Carry an epinephrine auto-injector (EpiPen) as prescribed until specialist clears you

›Wear medical alert identification stating history of hydatid cyst rupture and anaphylaxis

›Biphasic reactions can occur up to 72 hours after the initial event

›Warning signs to return to the emergency department immediately

›Sudden severe hives or swelling of face, lips, or throat

›Difficulty breathing or swallowing

›Sudden severe abdominal pain

›Yellowing of skin or eyes (jaundice)

›High fever with shaking chills

›Dizziness or fainting

›Nausea, vomiting that cannot be controlled

›Any new or worsening symptoms that concern you

›Follow-up appointments

›Surgeon follow-up within 1–2 weeks post-discharge

›Infectious disease or tropical medicine specialist within 2–4 weeks

›Ultrasound abdomen every 3–6 months for 2 years to monitor cyst regression

›Repeat blood tests (CBC and liver function) every 2 weeks while on albendazole

12References/r16

Guidelines and key sources

›WHO Informal Working Group on Echinococcosis (WHO-IWGE)

›WHO-IWGE cyst classification CE1–CE5 for staging and treatment guidance

›PAIR guideline: indications, contraindications, and procedural protocol

›WHO Technical Report Series 993: Echinococcosis

›International guidelines

›European Association for the Study of the Liver (EASL) clinical practice guidelines on echinococcosis

›WHO-IWGE consensus guidelines on treatment of uncomplicated CE

›Key references for emergency management

›Anaphylaxis management: World Allergy Organization (WAO) Anaphylaxis Guidelines 2020

›Surviving Sepsis Campaign guidelines for septic shock management

›Coding standards

›ICD-10 B67.0: Echinococcus granulosus infection of liver

›ICD-10 B67.1: Echinococcus granulosus infection of lung

›ICD-10 B67.2: Echinococcus granulosus infection of bone

›ICD-10 B67.8: Echinococcus granulosus infection, other and multiple sites

›ICD-10 B67.9: Echinococcus granulosus infection, unspecified

Evidence & Review

Evidence & Review